January 20, 2021

Health Canada says 9 adverse reactions after COVID-19 vaccine are in line with clinical trials

Health Canada received nine adverse medical reactions following the corona virus vaccination in Canada, but no evidence of unexpected side effects was found, federal public health officials said today.

At a press conference in Ottawa, Canada’s Chief Public Health Officer Dr. Theresa Tom said the federal government has launched a new website that will provide weekly reports on vaccine safety.

“Like any new initiative, we all have questions. These weekly reports on COVID-19 vaccine protection are aimed at providing Canadians with consistent access to reliable information that will enable them and their families to make informed and confident decisions about vaccination,” he said.

According to the website, nine people reported experiencing a total of 65 symptoms – eight of which were considered severe – until January. 1. Nine people received the Pfizer-Bioentech vaccine.

Vaccinations began on December 14, and the COVID-19 data task force – a volunteer team of educators and data analysts – has administered at least 234,000 doses so far, mostly to front-line health workers and long-term care residents and staff.

Adverse events can range from sores or mild fever at the injection site to serious problems such as severe allergic reactions.

Of those who reported severe symptoms, three experienced severe allergic reactions. One patient reported having a headache, one with facial paralysis, one with a cold, another with dizziness and one with pain.

The most serious adverse events reported so far are reported to be swelling of the needle, nausea and feeling of needles and needles.

The website states that the vaccine does not cover all the adverse events that people experience after receiving the vaccine.

READ  Kenny instructs MLAs not to leave Canada unless engaged in government business after ministerial leave

“The benefits of approved vaccines in Canada continue to outweigh the risks,” the site says.

No unexpected side effects

Dr. Supriya Sharma is the Chief Medical Adviser at Health Canada and oversees the vaccine review process. He said there were no reports of unexpected side effects to date from patients vaccinated against COVID-19.

“There are no serious adverse events, or even mild and moderate adverse events, which are different or different from what we have seen in clinical trials,” Sharma told The Canadian Press on Friday.

He said experts should answer two questions when reviewing data after vaccinations have been given. The first is whether anything unnoticed has occurred during clinical trials. Second, whether the documented side effects are more severe or greater in number than what the tests have seen.

Sharma said there were no answers to the two questions that have been asked so far in Canada.

“Clinical trials seem to be pretty representative,” he said.

A Govt-19 Vaccine Center at the Winnipeg Convention Center on January 1, 2021. (John Woods / The Canadian Press)

Canada last month approved two vaccines against COVID-19. One is a joint venture between the American pharmaceutical company Pfizer and the German biotechnology company Bioendech, and the other is produced by the American company Modernna.

In both the United States and Canada, immunizers experience allergic reactions and need immediate treatment if they need to be vaccinated.

Health Canada has advised it People who are allergic to any substance Pfizer-Bioentech and Modern Corona virus vaccines should not be given to them, and they should talk to a healthcare professional about any severe allergies or other health conditions they may have before receiving a corona virus vaccine.

The regulator is constantly reviewing data from two vaccine developers, British pharmaceutical company AstroZeneca and Johnson & Johnson’s subsidiary Johnson Inc., but is waiting for additional data from the companies. Sharma said Health Canada could not say when it would be ready to make a decision about the vaccine.

Both companies are expected to complete Phase 3 clinical trials in the United States this month.